NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis $0.54 -0.04 (-7.63%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$0.56 +0.03 (+4.71%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Invivyd Stock (NASDAQ:IVVD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Invivyd alerts:Sign Up Key Stats Today's Range$0.52▼$0.5950-Day Range$0.54▼$1.0252-Week Range$0.52▼$3.07Volume3.30 million shsAverage Volume3.86 million shsMarket Capitalization$158.49 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination. Invivyd was founded as Adagio Therapeutics and adopted its current name in 2022. The company is based in Waltham, Massachusetts, and its publicly described commercial activity is centered on the U.S. market.AI Generated. May Contain Errors. Read More Invivyd Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreIVVD MarketRank™: 3.301534356235 of 5 starsInvivyd scored higher than 66% of companies evaluated by MarketBeat, and ranked 198th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingInvivyd has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInvivyd has a consensus price target of $10.00, representing about 1,759.8% upside from its current price of $0.54.Amount of Analyst CoverageInvivyd has only been the subject of 4 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($0.51) to ($0.43) per share.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.00% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 9.66.Change versus previous monthShort interest in Invivyd has recently decreased by 2.27%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.53 News SentimentInvivyd has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Invivyd this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for IVVD on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $176,540.00 in company stock.Percentage Held by Insiders12.25% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IVVD Stock News HeadlinesInvivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 16 at 12:18 PM | marketscreener.comMInvivyd Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 16 at 7:01 AM | globenewswire.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 17 at 1:00 AM | Profits Run (Ad)Invivyd, Inc. (NASDAQ:IVVD) Stock Has Average Price Target of $10.00 According to BrokeragesNovember 16 at 1:45 AM | americanbankingnews.comInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 3, 2026 | globenewswire.comInvivyd, Inc. Presents VMS063, A Potential Best-In-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, At IDWeek 2026October 22, 2026 | marketscreener.comMInvivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026October 21, 2026 | globenewswire.comInvivyd, Inc. and The SPEAR Study Group Announce Initiation Of FLINTLOCK Phase 2 Study Of VYD2311, A Monoclonal Antibody For The Potential Treatment Of Long COVID Or Post ...October 14, 2026 | marketscreener.comMSee More Headlines IVVD Stock Analysis - Frequently Asked Questions How have IVVD shares performed this year? Invivyd's stock was trading at $2.47 at the start of the year. Since then, IVVD stock has decreased by 78.2% and is now trading at $0.5377. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) issued its quarterly earnings results on Monday, November, 16th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. The business had revenue of $15.45 million for the quarter, compared to the consensus estimate of $15.04 million. Invivyd had a negative trailing twelve-month return on equity of 59.73% and a negative net margin of 183.90%. When did Invivyd IPO? Invivyd (IVVD) raised $309 million in an initial public offering on Friday, August 6th 2021. The company issued 18,200,000 shares at $16.00-$18.00 per share. Who are Invivyd's major shareholders? Invivyd's top institutional shareholders include Soleus Capital Management L.P. (2.55%), State Street Corp (1.26%), Goldman Sachs Group Inc. (0.67%) and 49 Wealth Management LLC (0.03%). Insiders that own company stock include Adimab, Llc, Terrance Mcguire, Jill Andersen, Timothy Edward Lee, Robert D Allen III, William E Duke, Julie Green and Kevin F Mclaughlin. View institutional ownership trends. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invivyd own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invivyd investors own include D-Wave Quantum (QBTS), Rigetti Computing (RGTI), NVIDIA (NVDA), SoundHound AI (SOUN), BigBear.ai (BBAI), Lithium Americas (LAC) and Quantum Computing (QUBT). Company Calendar Last Earnings11/16/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IVVD's financial health is in the Yellow zone, according to TradeSmith. IVVD has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IVVD CIK1832038 Webwww.invivyd.com Phone781-819-0080FaxN/AEmployees122Year FoundedN/APrice Target and Rating Average Price Target for Invivyd$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+1,759.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.49 million Net Margins-183.90% Pretax Margin-183.90% Return on Equity-59.73% Return on Assets-48.97% Debt Debt-to-Equity RatioN/A Current Ratio5.87 Quick Ratio5.87 Sales & Book Value Annual Sales$53.43 million Price / Sales2.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.52Miscellaneous Outstanding Shares294,760,000Free Float258,651,000Market Cap$158.49 million OptionableOptionable Beta1.20 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IVVD) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.